EZH2 inhibition enhances the efficacy of an egfr inhibitor in suppressing colon cancer cells

Cancer Biology and Therapy

Volumn 15, Issue 12, 2014, Pages 1677-1687

  Katona, Bryson W ^a,b   Liu, Yuanyuan ^b,c   Ma, Anqi ^c   Jin, Jian ^d   Hua, Xianxin ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HUBEI CANCER HOSPITAL   (China)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Autophagy; Colon cancer; EGFR; Epigenetics; EZH2; Gefitinib; UNC1999

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; HISTONE H3; MICROTUBULE ASSOCIATED PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR EZH2; UNC 1999; UNCLASSIFIED DRUG; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SMALL INTERFERING RNA;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOLYSOSOME; AUTOPHAGOSOME; AUTOPHAGY; CELL COUNT; CELL PROLIFERATION; CLONOGENESIS; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; GENE SILENCING; HISTONE METHYLATION; HT 29 CELL LINE; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; COLON TUMOR; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION; GENETICS; METABOLISM; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SYNERGISM; GENE EXPRESSION; HUMANS; PHOSPHORYLATION; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84920279487     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.972776     Document Type: Article

References (32)

1. American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society, 2014.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62:220-41; PMID:22700443
3. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369:1023-34; PMID:24024839; http://dx.doi.org/10.1056/NEJMoa1305275
4. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358:1160-74; PMID:18337605; http://dx.doi.org/10.1056/NEJMra0707704
5. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011; 10:1533-41; PMID:21878654; http://dx.doi.org/10.1158/1535-7163.MCT-11-0047
6. Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell 2013; 154:1269-84; PMID:24034250; http://dx.doi.org/10.1016/j.cell.2013.08.015
7. Zou Y, Ling YH, Sironi J, Schwartz EL, Perez-Soler R, Piperdi B. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib. J Thoracic Oncol 2013; 8:693-702; PMID:23575415; http://dx.doi.org/10.1097/JTO.0b013e31828c7210
8. Li YY, Lam SK, Mak JC, Zheng CY, Ho JC. Erlotinibinduced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer 2013; 81:354-61; PMID:23769318; http://dx.doi.org/10.1016/j.lungcan.2013.05.012
9. Bokobza SM, Jiang Y, Weber AM, Devery AM, Ryan AJ. Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells. Oncotarget 2014; 5:4765-78; PMID:24946858
10. Dragowska WH, Weppler SA, Wang JC, Wong LY, Kapanen AI, Rawji JS, Warburton C, Qadir MA, Donohue E, Roberge M, et al. Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PloS One 2013; 8: e76503; PMID:24146879; http://dx.doi.org/10.1371/journal.pone.0076503
11. Eimer S, Belaud-Rotureau MA, Airiau K, Jeanneteau M, Laharanne E, Veron N, Vital A, Loiseau H, Merlio JP, Belloc F. Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer Biol Ther 2011; 11:1017-27; PMID:21508666; http://dx.doi.org/10.4161/cbt.11.12.15693
12. Xu L, Beckebaum S, Iacob S, Wu G, Kaiser GM, Radtke A, Liu C, Kabar I, Schmidt HH, Zhang X, et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol 2014; 60:590-8; PMID:24211739; http://dx.doi.org/10.1016/j.jhep.2013.10.028
13. Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X, Yuan GC, Orkin SH. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 2008; 32:491-502; PMID:19026780; http://dx.doi.org/10.1016/j.molcel.2008.10.016
14. McCabe MT, Creasy CL. EZH2 as a potential target in cancer therapy. Epigenomics 2014; 6:341-51; PMID:25111487; http://dx.doi.org/10.2217/epi.14.23
15. Shen L, Cui J, Liang S, Pang Y, Liu P. Update of research on the role of EZH2 in cancer progression. OncoTargets Ther 2013; 6:321-4; PMID:23589697; http://dx.doi.org/10.2147/OTT.S42453
16. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009; 625:131-42; PMID:19836388; http://dx.doi.org/10.1016/j.ejphar.2009.10.011
17. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51; PMID:16397526; http://dx.doi.org/10.1038/nrc1779
18. Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours-lessons from the past. Nat Rev Clin Oncol 2013; 10:256-66; PMID:23546521; http://dx.doi.org/10.1038/nrclinonc.2013.42
19. Benoit YD, Witherspoon MS, Laursen KB, Guezguez A, Beausejour M, Beaulieu JF, Lipkin SM, Gudas LJ. Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells. Exp Cell Res 2013; 319:1463-70; PMID:23588203; http://dx.doi.org/10.1016/j.yexcr.2013.04.006
20. Benoit YD, Laursen KB, Witherspoon MS, Lipkin SM, Gudas LJ. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells. J Cell Physiol 2013; 228:764-72; PMID:23001792; http://dx.doi.org/ 0.1002/jcp.24224
21. Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Falth M, Sultmann H, Holzer A, Hoppe-Seyler K, Hoppe-Seyler F. EZH2 depletion blocks the proliferation of colon cancer cells. PloS One 2011; 6: e21651; PMID:21765901; http://dx.doi.org/10.1371/journal.pone.0021651
22. Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ, Liu F, Gao C, Huang XP, Kuznetsova E, et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol 2013; 8:1324-34; PMID:23614352; http://dx.doi.org/10.1021/cb400133j
23. Barth S, Glick D, Macleod KF. Autophagy: assays and artifacts. J Pathol 2010; 221:117-24; PMID:20225337; http://dx.doi.org/10.1002/path.2694
24. Komatsu M, Kageyama S, Ichimura Y. p62/SQSTM1/ A170: physiology and pathology. Pharmacol Res 2012; 66:457-62; PMID:22841931; http://dx.doi.org/10.1016/j.phrs.2012.07.004
25. Tanida I, Minematsu-Ikeguchi N, Ueno T, Kominami E. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy 2005; 1:84-91; PMID:16874052; http://dx.doi.org/10.4161/auto.1.2.1697
26. Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, Maiuri MC, Kroemer G. Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta 2009; 1793:1524-32; PMID:19371598; http://dx.doi.org/10.1016/j.bbamcr.2009.01.006
27. Chen Y, Klionsky DJ. The regulation of autophagy-unanswered questions. J Cell Sci 2011; 124:161-70; PMID:21187343; http://dx.doi.org/10.1242/jcs.064576
28. Han CB, Li F, Ma JT, Zou HW. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 2012; 30:741-7; PMID:23075074; http://dx.doi.org/10.3109/07357907.2012.732159
29. Remon J, Moran T, Reguart N, Majem M, Carcereny E, Lianes P. Beyond EGFR TKI in EGFRmutant non-small cell lung cancer patients: main challenges still to be overcome. Cancer Treat Rev 2014; 40:723-9; PMID:24759598; http://dx.doi.org/10.1016/j.ctrv.2014.03.006
30. Mok TS, Lee K, Leung L. Targeting epidermal growth factor receptor in the management of lung cancer. Semin Oncol 2014; 41:101-9; PMID:24565584; http://dx.doi.org/10.1053/j.seminoncol.2013.12.010
31. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2014. http://www.R-project.org/
32. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. BioRxiv 2014. http://dx.doi.org/10.1101/002832